GLP-1 receptor agonist drugs as a protective factor against chronic kidney disease in patients with type 2 diabetes mellitus

• Autor(a) principal: Assunção, Izabely Lima
• Data de Publicação: 2021
• Outros Autores: Gonzalez, Giuliana Maria Morais, Silva, Vanessa Marques da, Carvalho , Clara Simplício Viana de, Machado, Arlene Gama Matos, Santos, Victor Martins dos, Pascoal, Gabriela de Abreu, Forest, Giovanna Oliveira, Sousa, Jaynnara Caroline Ferreira de, Fonseca, Isabel Alice Ramos, Silva, Luciana Sousa, Mendes, Laís Pereira, Mendes , Amanda Pereira, Britto, Filipe Augusto Lopes Cajubá de, Viana, Thassia Almeida Matos, Araújo , Maria Caroline Leal Borges de, Costa, Yvilla Cristina, Nascimento, Victoria Alves do, Meinertz , Laura Felipe, Chiacchio , Gabriel Machado, Costa, Matheus Medeiros, Cipriano, Amanda Mendonça Vieira, Souza , Daniel Geovane Silva, Gonzalez , Lethícia Maria Morais, Ferreira , Glória Maria Grangeiro
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/23517
• topic: Complicaciones de la diabetes; Enfermedad renal crónica.; Complicações do diabetes; Doença renal crônica.; Diabetes complications; Chronic kidney disease.

Type 2 diabetes mellitus (DM) develops due to peripheral insulin resistance, tied to secretory pancreatic fatigue, its pathophysiology involves genetic and environmental factors, such as poor diet and sedentary lifestyle. Diabetic patients have a risk factor for the development of microvascular lesions, such as retinopathy, neuropathy, nephropathy. To evaluate how GLP-1 receptor agonists act as a protective factor for chronic kidney disease in patients with type 2 diabetes mellitus. For the survey of articles in the literature, searches were conducted in the following databases: Latin American and Caribbean Literature in Health Sciences (LILACS), Medical Literature Analysis and Retrieval Sistem online (Medline), Scielo, and articles published in the period 2016-2021, in Portuguese, English and Spanish. From the studies, it was possible to perceive the intimate relationship between patients with type 2 DM and chronic kidney disease (CKD) and the nephroprotective function of GLP-1 analogues. As the development of microvascular lesions is usually chronic and silent, these patients should be monitored frequently. For patients with high chances of kidney injury, the use of GLP-1 analogues has been shown to be a great choice, because in addition to hypoglycemic agents they still have nephroprotective factor, through the reduction of the release of cytokines and hormones capable of directly harming renal cells.